Kezar Phase 2 MISSION trial: 64.7% overall renal response rate in lupus nephritis

Kezar Life Sciences, Inc.

11 of 17 patients (64.7%) achieved overall renal response (≥50% reduction in UPCR) at 6 months.
6 of 17 patients (35.2%) achieved complete renal response (UPCR ≤0.5, eGFR stable, steroids ≤10 mg/day).
Zetomipzomib well tolerated; most AEs mild-to-moderate; no Grade 3 infections reported.
Mean daily prednisone reduced from 19.2 mg at baseline to 9.1 mg at end of treatment.
Company plans continued development for lupus nephritis and evaluation for systemic lupus erythematosus.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.